Dr. Montgomery Rice will be formally recognized at the Atlanta Business Chronicle's second annual Health Care Champion Awards ceremony on March 20, 2025.

Recognizing a Visionary Leader in Advancing Healthcare Access for Minority and Vulnerable Populations Worldwide ATLANTA, GA - ...

Financial GeoVax Anticipates Significant 2025 Progress With Catalyst-Rich Milestones Across Key Programs 05.02.2025 / 15:06 CET/CEST The issuer is solely responsible for the content of this ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today outlined its 2025 strategic milestones ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and ...

This versatility allows GeoVax to develop vaccines targeting multiple aspects of a single pathogen or several pathogens simultaneously. Originally developed as a safer smallpox vaccine ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company specializing in vaccines and immunotherapies, has shared updates about its development-stage advanced Modified Vaccinia Ankara ...

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX – Get Free Report) have been given an average rating of “Buy” by the seven analysts that are currently covering the firm, Marketbeat reports.

GeoVax Labs has a 1 year low of $1.09 and a 1 year high of $11.18. GeoVax Labs ( NASDAQ:GOVX – Get Free Report ) last issued its quarterly earnings data on Tuesday, November 12th.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax’s ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...